Zealand Pharma (LSE:0NZU) - Stock Price, News & Analysis

0NZU Stock Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.

About the company

0NZU fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 26.72% per year

Analysts in good agreement that stock price will rise by 26%

Risk Analysis

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Zealand Pharma A/S Competitors

Genus

LSE:GNS

UK£1.1b

PureTech Health

LSE:PRTC

UK£564.7m

NIOX Group

AIM:NIOX

UK£275.6m

Bioventix

AIM:BVXP

UK£240.1m

Price History & Performance

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Price	kr.598.50
52 Week High	kr.749.00
52 Week Low	kr.212.20
Beta	0.67
1 Month Change	-16.93%
3 Month Change	35.53%
1 Year Change	165.63%
3 Year Change	202.43%
5 Year Change	355.65%
Change since IPO	793.28%

Recent updates

Shareholder Returns

	0NZU	GB Biotechs	GB Market
7D	0.3%	-2.4%	-1.4%
1Y	165.6%	-29.6%	-2.4%

Return vs Industry: 0NZU exceeded the UK Biotechs industry which returned -28.5% over the past year.

Return vs Market: 0NZU exceeded the UK Market which returned -1% over the past year.

Price Volatility

Is 0NZU's price volatile compared to industry and market?
0NZU volatility
0NZU Average Weekly Movement	10.2%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0NZU's share price has been volatile over the past 3 months.

Volatility Over Time: 0NZU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
1997	253	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
0NZU fundamental statistics
Market cap	kr.37.27b
Earnings (TTM)	-kr.703.74m
Revenue (TTM)	kr.342.79m

108.7x

P/S Ratio

-53.0x

P/E Ratio

Is 0NZU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0NZU income statement (TTM)
Revenue	kr.342.79m
Cost of Revenue	kr.688.10m
Gross Profit	-kr.345.31m
Other Expenses	kr.358.43m
Earnings	-kr.703.74m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 16, 2024

Earnings per share (EPS)	-11.30
Gross Margin	-100.74%
Net Profit Margin	-205.30%
Debt/Equity Ratio	0%

How did 0NZU perform over the long term?

See historical performance and comparison

0NZU Stock Overview

Rewards

Risk Analysis

Zealand Pharma A/S Competitors

LSE:GNS

UK£1.1b

LSE:PRTC

UK£564.7m

AIM:NIOX

UK£275.6m

AIM:BVXP

UK£240.1m

Price History & Performance

Recent News & Updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019)

Revenue misses expectations

New 90-day low: kr.192

New 90-day low: kr.202

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Third quarter 2020 earnings released: kr.5.76 loss per share

Revenue misses expectations

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

New 90-day low: kr.211

New 90-day high: kr.245

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

New 90-day low - kr.220

Shareholder Returns